Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging (PARENT-EAR)

4. september 2026 oppdatert av: Paula Tähtinen, Turku University Hospital

Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on clinical expertise.

Digital otoscopy combined with artificial intelligence (AI)-based image analysis has demonstrated high diagnostic accuracy in previous studies. In a recent study by our group, digital otoscopy with an automated neural network classifier reliably ruled out otitis media in children.

The PARENT-EAR randomized controlled pilot trial aims to evaluate whether parent-performed digital otoscopy at home, combined with retrospective AI analysis of captured TM images, can reduce physician visits due to suspicion of AOM. The study also assesses feasibility, diagnostic accuracy of parents after training, and potential effects on antibiotic use and healthcare utilization.

Methods and outcomes The PARENT-EAR trial is a randomized controlled pilot trial conducted at Vaasa Central Hospital and Turku University Hospital. Recruitment will occur between September and December 2026 (extended if necessary), with follow-up ending May 31, 2027 (5-9 months per participant).

Children aged 12 to 47 months with at least one AOM episode in the past 12 months will be randomized 1:1 using permuted block randomization. Exclusion criteria include tympanostomy tubes, tympanic membrane perforation, middle ear effusion at recruitment, immunosuppression, previously diagnosed hearing loss or anatomical abnormalities predisposing to AOM, and otoscopy experience of the parent.

Intervention group:

Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.

Control group:

Standard care without home otoscopy. Parents complete the same symptom diary and seek care according to usual practice.

Statistical analyses will compare outcomes between groups. AI-based TM classification will be compared against expert panel evaluation.

This is a pilot study with a target sample size of 20 children per arm, limited by device availability.

Ethical aspects, data collection and handling The study will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all parents after provision of oral and written information. Participation is voluntary, and families may withdraw at any time. Investigators may discontinue participation if deemed in the child's best interest.

The digital otoscope is a CE-marked Class I medical device used solely for visual inspection of the tympanic membrane. Pneumatic pumps are not provided. Potential risks include minor ear canal abrasions or discomfort; serious adverse events are considered rare. Any adverse events will be managed according to standard clinical practice and reported to relevant authorities when required. The study is investigator-initiated. The device manufacturer provides the otoscopes but has no role in study design, data access, or analysis.

Data will be collected via paper symptom diaries, monthly REDCap questionnaires (University of Turku), and national electronic health records (Kanta). TM images and videos will be securely stored and imported into a research database with relevant metadata.

All data will be handled in accordance with the EU General Data Protection Regulation (GDPR 2016/679). Study data will be pseudonymized and identified only by study ID numbers. The key linking personal identifiers to study IDs will be stored separately and securely. Paper diaries will be destroyed after digitalization. Consent includes permission to access health records and to use collected images and data for scientific purposes. Results will be published in peer-reviewed journals and as part of a doctoral thesis.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Pohjanmaa
      • Vaasa, Pohjanmaa, Finland, 65130
        • Rekruttering
        • Vaasa Central Hospital
        • Ta kontakt med:
        • Ta kontakt med:
    • Southwest Finland
      • Turku, Southwest Finland, Finland, 20521
        • Har ikke rekruttert ennå
        • Turku University Hospital
        • Ta kontakt med:
        • Ta kontakt med:
          • Lotta E Ivaska, MD, PhD
          • Telefonnummer: +35823130000
          • E-post: lesaar@utu.fi

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • At least one episode of AOM within the last 12 months
  • Family speaks fluent Finnish

Exclusion Criteria:

  • Tympanostomy tubes or perforation of the TM, or scheduled for upcoming tympanostomy
  • Middle ear fluid at the time of recruitment
  • Previously diagnosed hearing loss
  • Immunosuppressive disorder or medication, excluding inhaled corticosteroids
  • Anatomic defect or anomaly affecting the susceptibility to AOM
  • Previous otoscopy experience of the participating parent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intervention group
Intervention group to receive the digital otoscope
Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.
Ingen inngripen: Control group
Control group with no intervention

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of physician visits due to suspected AOM
Tidsramme: 5 to 9 months, depending on date of recruitment
Number of physician visits due to suspected AOM
5 to 9 months, depending on date of recruitment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Agreement between parent interpretation, AI classifier, and expert gold standard
Tidsramme: 5 to 9 months, depending on date of recruitment
Parent's interpretation of the tympanic membrane image is retrospectively compared to the expert's gold standard and classification by an artificial intelligence classifier
5 to 9 months, depending on date of recruitment
Antibiotic prescription rates
Tidsramme: 5 to 9 months, depending on date of recruitment
Antibiotic prescription rates for AOM in both arms
5 to 9 months, depending on date of recruitment
Adverse events related to otoscopy
Tidsramme: 5 to 9 months, depending on date of recruitment
Adverse events, such as abrasion, related to otoscopy in the experimental group
5 to 9 months, depending on date of recruitment
AOM-related complications
Tidsramme: 5 to 9 months, depending on date of recruitment
AOM-related complications, such as mastoiditis, in both arms
5 to 9 months, depending on date of recruitment
Daycare absence
Tidsramme: 5 to 9 months, depending on date of recruitment
Child's absence from daycare due to suspected AOM
5 to 9 months, depending on date of recruitment
Parental work absenteeism
Tidsramme: 5 to 9 months, depending on date of recruitment
Parental work absenteeism due to suspected AOM
5 to 9 months, depending on date of recruitment
Parental satisfaction on a visual analog scale (VAS)
Tidsramme: 5 to 9 months, depending on date of recruitment
Parental satisfaction in the experimental group of AOM management with parent-led digital otoscopy
5 to 9 months, depending on date of recruitment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Paula A Tähtinen, MD, PhD, Department of Paediatiatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Finland

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. september 2026

Primær fullføring (Antatt)

31. mai 2027

Studiet fullført (Antatt)

31. august 2027

Datoer for studieregistrering

Først innsendt

27. mai 2026

Først innsendt som oppfylte QC-kriteriene

6. juni 2026

Først lagt ut (Faktiske)

10. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

4. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • VARHA/4418/13.02.01/2026

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Deidentified participant data will be made available upon reasonable request from the corresponding author.

IPD-delingstidsramme

Study protocol will be published as supplementary material alongside the study manuscript alongside publication.

Tilgangskriterier for IPD-deling

Deidentified participant data will be made available to fellow researchers upon reasonable request from the corresponding author.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere